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after adjusting for age, gender, gout treatment, comorbidities, and medication use.
RESULTS: We identiﬁ ed 4821 AMI cases of which 1410 were women. The adjusted
odds ratio (OR [95% CI]) of AMI among women with gout was 1.62 (1.21–2.16), 
higher than the adjusted OR for men (1.12 [0.99–1.26]; p-value for interaction 0.01). 
When we combined both women and men in our analyses, we found an overall 
adjusted OR of 1.15 (1.06–1.25). CONCLUSIONS: Using population-based data, we 
found a 62% increased risk for AMI among elderly women with gout, and a 15%
increased risk for elderly gout patients overall. The association between hyperurice-
mia, a known precursor to gout, and cardiovascular disease provides a potential 
explanation for our ﬁ ndings. Gender differences in serum uric acid levels and metabo-
lism may further explain the difference in risks between women and men. Findings 
provide support for the aggressive management of cardiovascular risk factors in gout
patients.
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COMPARISON OF 3 COMORBIDITY MEASURES AFFECTING PHYSICAL 
FUNCTION AND QUALITY OF LIFE FOR PATIENTS WITH ANKYLOSING
SPONDYLITIS
Gooch K1, Wong R2
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OBJECTIVES: In clinical studies, comorbidity measurement refers to assessment of 
total burden of illnesses across multiple health conditions unrelated to the patients’ 
disease under study. In non-randomized clinical studies and epidemiology studies,
adjustment for comorbidity is often undertaken to ensure outcomes are not directly
affected by comorbidities. This analysis compared 3 measurements of comorbidities
and their effects on physical function and quality of life with data from a randomized 
controlled trial of adalimumab in ankylosing spondylitis (AS). METHODS: Data
were derived from the Adalimumab Trial Evaluating Long-Term Efﬁ cacy and Safety
in AS (ATLAS). Comorbidity indices at baseline were calculated as Chronic Disease
Score (CDS), number of separate prescription medications (prescription count), and
number of concurrent illnesses (concurrent illness count). Medications taken speciﬁ -
cally for the treatment of AS were excluded from the CDS and prescription medication 
count calculations. Univariate associations between each of the 3 indices and a physi-
cal function index (SF-36 PCS) and AS disease-speciﬁ c quality of life (ASQOL) at 
Week 12 were assessed. Correlations with each comorbidity measurement were ascer-
tained. Model selection (Alkaike’s Information Criterion [AIC]) was used to identify 
the best comorbidity measure for predicting SF-36 PCS and ASQOL. RESULTS: A 
total of 315 patients were included in the analysis. Their mean age was 42.2 years,
and most were male (74.9%). At the univariate level, all 3 indices were signiﬁ cant 
predictors of SF-36 PCS score (p  0.02), However, only CDS and prescription medica-
tion count were signiﬁ cantly associated with ASQOL at Week 12. All 3 indices were
well-correlated with each other (range 0.750–0.917). The AIC model demonstrated 
that CDS was the best predictor of SF-36 PCS and ASQOL. Prescription count was 
the second-best ranked measure for both outcomes. CONCLUSIONS: The CDS is a
suitable measure for comorbidity adjustment in examining physical function and 
quality of life for AS patients.
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RISK FACTORS FOR INCIDENT GOUT AMONG WOMEN: 
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OBJECTIVES: Despite increasing incidence and substantial prevalence of gout among 
women, particularly among elderly, no prospective data on the risk factors for gout 
are available among women. We prospectively evaluated purported risk factors for
the risk of incident gout among women and compared them with men. METHODS:
Using data from the Framingham Heart Study, we prospectively examined over a 52-
year period (1948–2001) the relation between prior serum uric acid levels and the risk 
of incident gout in 2,470 women and 1,951 men. We used Cox proportional hazards 
models to estimate the relative risk for incident gout by uric acid level after adjusting
for age, body mass index, blood glucose level, blood cholesterol level, hypertension,
use of diuretics, alcohol consumption, educational level and menopausal status.
RESULTS: Over a 28-year median follow-up, we documented 304 incident cases of 
gout, 104 among women. The incidence rates of gout increased with increasing serum 
uric acid levels, similar to men. For uric acid levels of 5.0, 5.0–5.9, 6.0–6.9, 7.0–7.9 
and q8.0 mg/dL the incidence rates of gout per 1000 person-years were 0.81, 1.42, 
1.83, 6.75, and 13.09, respectively (p for trend 0.0001). The multivariate relative 
risk (95% CI) for incident gout for every 1.0 mg/dL increase in serum uric acid level 
was 1.57 (1.38–1.78) among women and 1.52 (1.36–1.71) among men. Other signiﬁ -
cant predictors of gout in women were age, obesity, hypertension, blood glucose level 
and diuretic use. CONCLUSIONS: These prospective data indicate that higher levels 
of serum uric acid increase the risk of gout among women in a graded manner, similar 
to men, and support the notion that serum uric acid is a reliable surrogate marker
and precursor of incident gout among women as well. Age, obesity, hypertension, 
blood glucose level and diuretic use were associated with the risk of incident gout
among women.
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FACTORS INFLUENCING THE LENGTH OF STAY AND TOTAL CHARGES
FOR PEDIATRIC PATIENTS DIAGNOSED WITH OSTEOMYELITIS
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OBJECTIVES: Osteomyelitis is an infection of the bone caused by an untreated injury.
Osteomyelitis can also come from an infection from another part of the body, such 
as a urinary tract infection that can spread to the bone through the blood. The purpose 
of this study is to determine what factors can inﬂ uence a pediatric patient’s stay in the
hospital when the patient has a diagnosis of osteomyelitis. METHODS: In order to
look at the length of stay and total charges for the patient’s stay in the hospital, we
used table analysis, summary statistics, one way frequency, kernel density, logistic
regression, and linear regression. Kernel density examines the entire population dis-
tribution. Logistic regression gives a prediction of the probability of occurrence. Linear
regression analyzes the effect of one variable on another. The data were taken from
the 2005 National Inpatient Sample with a total of 3972 patients; 1971 have osteo-
myelitis and the remaining 2001 patients form a control group. RESULTS: The 
average length of stay in the hospital was about eight days. For patients who had 
osteomyelitis, the peak value of total charges was around $10,000, and those who did
not have the disease had a peak value of total charges of around $5,000. The variables 
that are signiﬁ cant on total charges are died, length of stay, race, bacterial infection, 
episodic mood disorders, arthrocentesis, magnetic resonance, incision, excision, and 
division, other incision with drainage, injection of antibiotic, and spinal tap. CON-
CLUSIONS: Generally, patients who have osteomyelitis have a longer hospital stay
and a higher bill compared to those that do not. The procedures performed on a 
patient inﬂ uence their length of stay and total charges. Length of stay is inﬂ uenced
more by invasive procedures and total charges are inﬂ uenced on length of stay and 
the number of procedures performed.
PMS6
DEVELOPMENT OF TESTS FOR DIAGNOSIS OF RHEUMATOID
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OBJECTIVES: New therapeutic options for rheumatoid arthritis (RA) have shifted
the focus of treatment to early, aggressive intervention aimed at preventing further
joint damage. However, early diagnosis has proved challenging, and recent efforts have
been made to identify new diagnostic tests. We systematically reviewed the literature 
to assess the current status of tests for early diagnosis of RA. METHODS: We searched 
English-language MEDLINE-indexed publications in the 5 years prior to August 2008 
concerning tests and biomarkers for early diagnosis of RA. We also searched non-
MEDLINE-indexed sources such as organization websites, meeting abstracts, and
governmental publications using the same keywords. RESULTS: We identiﬁ ed 94 
primary studies from MEDLINE pertaining to tests or biomarkers for early diagnosis 
of RA. Non-MEDLINE sources yielded an additional 56 articles for a total of 150 
reviewed for this study. In practice, no single test has proved sufﬁ ciently sensitive and 
speciﬁ c for the diagnosis of RA. Tests currently in use, including the acute phase bio-
markers erythrocyte sedimentation rate and C-reactive protein and the autoantibody 
rheumatoid factor (RF), are relatively nonspeciﬁ c for RA. Recent efforts have focused 
on identifying new biomarkers with greater RA speciﬁ city. These include many auto-
antibodies, immune system biomarkers, and biomarkers of collagen breakdown and
bone erosion. The autoantibody anti-cyclic citrullinated peptide (anti-CCP) offers high 
speciﬁ city, but lower sensitivity than RF. Newer-generation anti-CCP assays provide
improved sensitivity over ﬁ rst-generation anti-CCP assays, but sensitivity still pre-
cludes their use as sole diagnostic tests for RA. The clinical utility of anti-CCP tests 
can be improved by combining with other assays such as RF, and provide particular 
value in predicting the development of persistent and/or erosive RA. CONCLUSIONS:
Newer generations of the autoantibody anti-CCP assay offer high speciﬁ city for RA 
and appear promising as a diagnostic test in combination with other tests with greater 
sensitivity.
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OBJECTIVES: To evaluate the long-term effectiveness of inﬂ iximab in the treatment
of rheumatoid arthritis (RA) in the actual practice setting. METHODS: A retrospective
chart review was conducted in six rheumatology clinics across the US. RA patients 
with a ﬁ rst inﬂ iximab encounter occurring between 2002 and 2004 were identiﬁ ed. 
Patients were required to have a minimum of 12-months of continuous records prior 
to the index inﬂ iximab date and were followed for up to 24-months after therapy
initiation. Effectiveness was deﬁ ned as reductions in joint pain, swelling, stiffness, and 
fatigue scores of 1 point (range from 0 to 10). Overall clinical improvement was
measured as a combination of pain, swelling, stiffness, and fatigue scores. Wilcoxon
Signed-Rank Tests were performed to test if there were statistically signiﬁ cant changes
from baseline. Also, biomarker test results, C-reactive protein (CRP) and erythrocyte 
sedimentation rate (ESR), were collected and compared to the baseline results.
RESULTS: A total of 266 inﬂ iximab patients were identiﬁ ed (72.9% female; average
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age  57.6 years). Two years after initiation of treatment, 48.7% patients showed 
overall clinical improvement. On average, patients received 367.5 days treatment after
the index date. Patients experienced improvements from baseline in all measures: joint
pain (4.0 vs. 4.3), joint swelling (3.0 vs. 3.2), stiffness (3.6 vs. 3.8), fatigue (4.2 vs. 
4.4), CRP (3.1 vs. 4.1), and ESR (24.5 vs. 31.2) (all P  0.001). Percentages of patients 
improved 1 point were 36.9% (joint pain), 38.0% (joint swelling), 28.2% (stiffness),
27.4% (fatigue), 94.1% (CRP), and 97.5% (ESR). CONCLUSIONS: Understanding 
the real world effectiveness of RA therapies under actual practice conditions is impor-
tant in the treatment decision process. This chart review indicates that inﬂ iximab
therapy had good long-term effectiveness in the treatment of RA. Studies to better 
understand the determinants of treatment adherence beyond clinical effectiveness are 
recommended.
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BIOLOGIC THERAPY REDUCES PATIENT-REPORTED SEVERITY OF
RHEUMATOID ARTHRITIS IN THE REAL WORLD SETTING
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OBJECTIVES: To evaluate the clinical effectiveness of biologic therapies in the treat-
ment of rheumatoid arthritis (RA) as measured by change in disease severity.
METHODS: Patient self-reported data were collected from the 2008 Rheumatoid 
Arthritis Patient Study. Patients with RA were asked to rate their current disease 
severity (mild, moderate or severe), as well as severity at the time of diagnosis and 
before treatment. Comparisons were made between respondents who received biologic
therapies (abatacept, adalimumab, etanercept, inﬂ iximab, or rituximab) versus those 
treated with non-biologic treatments. An improvement in severity is deﬁ ned as less 
severe (changes from severe/moderate to moderate/mild) after the current treatment. 
RESULTS: Of 2048 respondents to the survey, the mean age was 51.9, and 74.3%
were female. The average duration from RA diagnosis was 11.9 years. For patients 
treated with biologic therapies, the average duration of the treatment was 3.7 years. 
There were no statistical signiﬁ cant differences in age, gender and duration from RA
diagnosis between patients who were treated with a biologic therapy versus those who
were not. At baseline more patients reported their disease status as severe (47.2%) in
the biologic group, compared to patients in the non-biologic group (21.3%). Only 
9.7% of patients in the biologic group versus 29.5% of patients in the non-biologic 
group reported their disease status as mild. However, 44.6% of patients in the biologic 
group versus 25.9% of the non-biologic group reported an improvement in severity 
after the current treatment, while 11.6% of patients in the biologic group versus
15.3% of the non-biologic group reported increased severity in disease state (chi 
square P  0.001) after the current treatment. CONCLUSIONS: In the real world 
setting, RA patients treated with biologic therapies self-reported more severe disease 
than patients treated with non-biologic therapies. Biologic therapies signiﬁ cantly
reduced patient-reported RA disease severity, compared to non-biologic therapies.
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TREATING ARTHRITIS OF THE KNEE: THE IMPACT ON PAIN IN
PATIENTS’ EVERYDAY LIVES
Taieb C
Pierre Fabre, Boulogne, France
Arthritis of the knee is a real public health problem. Its prevalence is estimated at
6.1% of adults aged over 30 years, according to data from the Framingham Study. 
OBJECTIVES: To observe, in real use conditions, the effects obtained by Hyaluronic
acid in the treatment of arthritis of the knee combined with a prescription of Sodium 
chondroitine sulfate between 2 treatments. METHODS: A longitudinal, prospective
observation programme. RESULTS: Forty-two patients were treated with Hyaluronic
acid and Soduium chondroitine sulfate, 19 patients were treated on the left side 
of the knee and 22 on the right side, with hyaluronic acid. At inclusion, average pain
during daily life activities was 53,289 o 20,836, at W18, 37,963 o 17,173 and at M6,
35,625 o 17,956. Development of the pain during daily life activities between inclusion
and W18 was signiﬁ cant (p  0.0056) as was the same between inclusion and M6
(p  0.0011). At inclusion, average pain at rest was 29,167 o 16,889, at W18, 19,792
o 14,255 and at M6, 19,217 o 17,399. Development of pain at rest between inclusion 
and W18 was not signiﬁ cant (p  0.0594) (however the p-value was very close to
0.05  .  .  .) as was the same between inclusion and M6 (p  0.0619). CONCLUSIONS:
The reduction of the pain – which was signiﬁ cant during patients’ daily activities at
18 weeks, and then sustained at 6 months – is a testimony to the relevance of this
treatment protocol. A greater number of trial subjects would make it possible to
conﬁ rm the signiﬁ cance of the reduction of pain at rest.
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REATED WITH ABATACEPT OR INFLIXIMAB
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OBJECTIVES: To determine dosing patterns associated with real-world treatment of 
rheumatoid arthritis (RA) patients with inﬂ iximab or abatacept. METHODS: An 
observational, retrospective (cohort) study of patients new to abatacept and inﬂ iximab 
was conducted using the PharMetrics Patient-Centric Database. All adult patients with
at least one claim of RA diagnosis at or prior to initial treatment with inﬂ iximab or 
abatacept from March 2006 to June 2007 were selected. Patients were identiﬁ ed and 
followed for at least 6 months based on their ﬁ rst infusion claim for inﬂ iximab or 
abatacept with no claims for any other biologic in the prior 6 months. Abatacept and 
inﬂ iximab cohorts were compared with respect to baseline characteristics and occur-
rence of upward dose adjustments (increase in dose or frequency). RESULTS: Forty 
abatacept and 216 inﬂ iximab patients were identiﬁ ed as new to biologic therapy. The
two cohorts were generally similar, however 47.5% of initial infusions for abatacept
patients were prescribed by a rheumatologist (also, 15% by primary care physician
(PCP) and 37.5% unknown), compared to 72.7% for inﬂ iximab patients (with 4.6% 
by PCP and 22.6% unknown). Abatacept patients were less likely to experience
upward dose adjustment than inﬂ iximab (10% vs. 57.9%, respectively). Multivariable 
Cox proportional hazards modeling (adjusted for age, gender, Charlson Comorbidity 
Index, and 1-year pre-index RA-related costs) determined that inﬂ iximab patients were 
more likely to experience upward dose adjustment than abatacept patients (HR  5.5, 
95% conﬁ dence interval  2.0–14.9, p  0.001). CONCLUSIONS: Upward dose 
adjustment with some biologic therapies is common and may lead to unexpectedly 
higher treatment costs with additional safety considerations. In this study, upward
dose adjustment appears to be less likely in patients started on abatacept than inﬂ ix-
imab. Further research should determine if the ﬁ xed dosing pattern observed with 
abatacept continues over time, as health care providers and patients become more 
familiar with this biologic.
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RELATIONSHIP BETWEEN LEVELS OF PHYSICAL ACTIVITY AT WORK 
AND PREVALENCE OF ARTHRITIS AMONG WORKING POPULATION
Bali V, Khan N
University of New Mexico, Albuquerque, NM, USA
OBJECTIVES: Arthritis is the most common chronic illness in the US. Various studies
have found association between arthritis and physical demands of work. This study 
determines the relationship between physical activity at work and prevalence of 
arthritis among working population. METHODS: To distinguish between arthritic
and non arthritic population we used question from the 2007 Behavioral Risk Factor
Surveillance System (BRFSS) that indicates whether an individual was suffering from 
arthritis that had been diagnosed by physician. We also determined an individual level 
of physical activity at work through the question that classiﬁ es an individual level of 
physical activity at work into three levels. RESULTS: The sample consists of 205,533 
respondents out of which (46, 078) 22.42% had arthritis and (15, 9455) 77.58% did
not have any type of arthritis. Results from the logistic regression showed signiﬁ cant 
relationship between prevalence of arthritis and gender, age, race, education, income,
reported health status, BMI, health coverage and physical activity at work (A  0.05). 
There was inconsistent relationship among the level of physical activity and prevalence 
of arthritis as people having moderate physical activity had lesser odds (O.R.0.965, 
95% CI: 0.938–0.994) of suffering from arthritis i.e. one unit increase in moderate 
physical activity at work was associated with 3.5% decrease in the odds of suffering 
from arthritis. However, people having heavy physical activity at work had greater
odds of (O.R.1.265, 95% CI: 1.220–1.311) of suffering from arthritis indicating that 
one unit increase in heavy physical activity was associated with 27% increase in the 
odds of suffering from arthritis. CONCLUSIONS: There is a need to investigate in 
greater detail the role of physical activity at work in conjunction with other factors 
on the prevalence of arthritis. This investigation can help in identifying people sus-
ceptible to develop arthritis along with the factors responsible for their illness.
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FIBROMYALGIA: RUSSIAN RHEUMATOLOGISTS’ KNOWLEDGE
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CONTEXT: Fibromyalgia syndrome (FMS) is an under-diagnosed. OBJECTIVES: To 
describe Russian rheumatologists’ knowledge of ﬁ bromyalgic patients. METHODS:
The questionnaire was sent to a random sample of Russian practitioners, who were 
answering the same questionnaire as that used by French practitioners in 2003.
RESULTS: The average number of patients seen daily by each practitioner was 58
(median 36 patients) 88% and 75% of the doctors claimed, individually, that they 
had not received any education on ﬁ bromyalgia or chronic fatigue during their medical
studies. During their professional activity, 53.9% of the doctors have still not had any
professional training on ﬁ bromyalgia. One percent of the doctors believed that ﬁ bro-
myalgia does not exist, while 36.5% believed that ﬁ bromyalgia is an illness and 63.2%
that it is a syndrome. Forty percent of the doctors who answered were continuing to 
treat ﬁ bromyalgic patients, 28% referred them to a specialist rheumatologist, 14% to 
a neurologist and 9% to a psychiatrist. Excessive fatigue, diffuse pain, a tendency
to feel depressed, anxious and sad, and muscle weakness were recognised respectively
as being the main symptoms of ﬁ bromyalgia by 64, 77, 64 and 45 % of the rheuma-
tologists respectively. Digestive problems, palpitations, swollen joints and radiological 
irregularities were recognised as being the main symptoms of ﬁ bromyalgia by 10, 13, 
12 and 9% of the rheumatologists respectively. CONCLUSIONS: As in EC countries, 
a wide-scale training effort should be made in order to improve the diagnosing of 
patients. The data collected via these evaluations was close to the results for France.
